JBJ-04-125-02 is a mutant-selective EGFR allosteric inhibitor with potential anticancer activity. As a single agent, it can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo. The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone. Note: JBJ-04-125-02 is a racemic mixture, which was described in Cancer Discov. 2019 Jul;9(7):926-943.
MedKoo Cat#: 558957
Name: JBJ-04-125-02
CAS#: 2140807-05-0 (racemic)
Chemical Formula: C29H26FN5O3S
Exact Mass: 543.1740
Molecular Weight: 543.68
Elemental Analysis: C, 64.07; H, 4.82; F, 3.49; N, 12.88; O, 8.83; S, 5.90
The following data is based on the product molecular weight 543.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
